UltraGreen.ai Limited Gains Singapore Nod for Verdye, Boosting Southeast Asia Growth

SGX Filings
05/05

UltraGreen.ai Limited (ULG) said on May, 5 2026 that it has received regulatory approval in Singapore for Verdye, its indocyanine green injection used in fluorescence-guided surgery.

The green light in Singapore, a key medical hub for the region, supports the company’s strategy to expand access to fluorescence-guided procedures across Southeast Asia. Verdye is now cleared in 41 countries.

With the approval, UltraGreen.ai plans to deepen collaborations with Singaporean healthcare institutions and accelerate commercial rollout of its integrated platform, which combines pharmaceutical agents, imaging hardware and AI-based data tools.

The company noted that its IC-Flow imaging system is authorised in 45 markets worldwide. The latest milestone follows its recent initial public offering and Verdye’s clearance in the Philippines.

UltraGreen.ai, headquartered in Singapore with operations in the United States, Ireland and other Asia-Pacific locations, develops fluorescence imaging solutions aimed at enhancing surgical precision. For additional details, visit the company’s website.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10